Update on Efficacy of Treatments for Cutaneous Candidiasis
A review finds that fluconazole is the only commercially available evidence-based option for systemic treatment of cutaneous candidiasis.
Fungal Infections
Olorofim Receives Breakthrough Therapy Designation for Invasive Fungal Infections
The FDA has granted Breakthrough Therapy designation to olorofim for the treatment of invasive mold infections.
Oral Ibrexafungerp Effective in Vulvovaginal Candidiasis Trial
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Higher Frequency of C albicans After Root Canals in Patients With Type 2 Diabetes
Patients with a long-term history of type 2 diabetes mellitus (T2DM) carried Candida albicans in their dental root canals more frequently when they have a primary endodontic infection.
Oral Amphotericin B Formulation Gets Orphan Drug Status for Cryptococcosis
The Food and Drug Administration (FDA) has granted Orphan Drug designation to MAT2203 (Matinas BioPharma) for the treatment of cryptococcosis.
Novel Antifungal Gains Fast Track Designation for Seven Indications
The FDA has granted Fast Track designations to both the oral and intravenous formulations of fosmanogepix for 7 antifungal indications.
ATS Guideline Outlines Lab Tests for Diagnosis of Fungal Infections
Guideline addresses lab testing for diagnosis of fungal infections in pulmonary medicine, critical care
Toenail Onychomycosis: Treatment Options Evaluated
A total of 26 RCTs with 8136 patients were included in this network meta analysis.
Trends in Histoplasma-Associated Immune Reconstitution Inflammatory Syndrome
Although incidence of histoplasma-associated immune reconstitution inflammatory syndrome is low, it still generates significant morbidity in people living with HIV.
Efficacy Evaluation for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis
Oral voriconazole may be more effective than oral itraconazole for initial maintenance therapy in patients with chronic pulmonary aspergillosis, according to a study published in Clinical Infectious Diseases.1 Currently, there are 4 oral anti-Aspergillus agents available (itraconazole, voriconazole, posaconazole, and isavuconazole) and while various studies have evaluated treatments for chronic pulmonary aspergillosis with itraconazole and…
Next post in Respiratory
